Labcorp Still Sees 2026 Free Cash Flow Outlook
Labcorp still sees its 2026 free cash flow outlook.
Related stories
Pagaya Reports $50 Million GAAP Net Income in Q3
Pagaya reported $50 million in GAAP net income, up $27 million year over year, and said it delivered record performance across key metrics.
M impact | EARNINGS | Oct 29, 2026, 11:07 AM UTC
Builders FirstSource Reports Q3 Adjusted EPS of $1.51 per Share
Builders FirstSource reported Q3 adjusted EPS of $1.51 per share, versus a FactSet estimate of $1.06.
M impact | EARNINGS | Oct 29, 2026, 11:05 AM UTC
Garrett Motion Posts Q3 EPS of $0.51 vs. FactSet Estimate of $0.45
M impact | EARNINGS | Oct 29, 2026, 11:05 AM UTC
Bristol Myers cuts profit target despite new-drug momentum
Reuters reports that new medicines are boosting Bristol Myers, but the company has lowered its profit target.
M impact | EARNINGS | Oct 29, 2026, 11:04 AM UTC
Bristol Myers Squibb Sees FY Adjusted EPS of $6.35-$6.55
The outlook compares with an IBES estimate of $6.49.
M impact | EARNINGS | Oct 29, 2026, 11:04 AM UTC
Bristol Myers Squibb Sees FY Adjusted Revenue of $49.75B-$50.25B
The company’s fiscal-year adjusted revenue outlook is $49.75 billion to $50.25 billion, versus an IBES estimate of $49.89 billion.
M impact | EARNINGS | Oct 29, 2026, 11:04 AM UTC